Cravath’s London Office Moves to 100 Cheapside
Joyce Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
November 18, 2025
Axalta’s $25 Billion Merger of Equals with AkzoNobel
On November 18, 2025, Axalta Coating Systems Ltd. (“Axalta”) and Akzo Nobel N.V. announced that they have entered into a definitive agreement to combine in an all‑stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Cravath is representing Axalta in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Deals & Cases
October 02, 2025
Occidental’s $9.7 Billion Sale of OxyChem to Berkshire Hathaway
On October 2, 2025, Occidental, an international energy company, and Berkshire Hathaway announced a definitive agreement for Berkshire Hathaway to acquire Occidental’s chemical business, OxyChem, in an all‑cash transaction for $9.7 billion, subject to customary purchase price adjustments. Cravath is representing Occidental in connection with the transaction.
Deals & Cases
August 07, 2025
Paramount Global Completes Merger with Skydance
On August 7, 2025, Paramount Global and Skydance Media (“Skydance”) announced the completion of their merger, creating a standalone global media and entertainment company, Paramount, a Skydance Corporation (“Paramount”). Paramount Class B shares will begin trading today on the Nasdaq Stock Market LLC under “PSKY.” Cravath represented the Paramount Special Committee in connection with the transaction.
Joyce Law concentrates her practice on real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work and leasing transactions. Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law’s clients have included Martin Marietta Materials, The Walt Disney Company, IBM, INEOS, Thermo Fisher Scientific, Ashland, Valvoline, Ahold Delhaize, Kraft Foods, Bristol‑Myers Squibb, Unilever, Jones Apparel Group, Morgan Stanley, Westbrook Partners and The Dermot Company.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Education
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
Admitted In
- New York
Deals & Cases
November 18, 2025
Axalta’s $25 Billion Merger of Equals with AkzoNobel
On November 18, 2025, Axalta Coating Systems Ltd. (“Axalta”) and Akzo Nobel N.V. announced that they have entered into a definitive agreement to combine in an all‑stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion. Cravath is representing Axalta in connection with the transaction.
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
November 03, 2025
Kenvue’s $48.7 Billion Acquisition by Kimberly‑Clark
On November 3, 2025, Kenvue Inc. (“Kenvue”), a global consumer health leader, and Kimberly‑Clark Corporation (“Kimberly‑Clark”), a global personal care leader, announced an agreement under which Kimberly‑Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at an enterprise value of approximately $48.7 billion, based on the closing price of Kimberly‑Clark common stock on October 31, 2025. Under the terms of the agreement, which has been unanimously approved by each company’s Board of Directors, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly‑Clark shares for each Kenvue share held at closing. Upon closing of the transaction, current Kenvue shareholders are expected to own approximately 46% and current Kimberly‑Clark shareholders are expected to own approximately 54% of the combined company on a fully diluted basis. Cravath is representing Kenvue in connection with the transaction.
Deals & Cases
October 02, 2025
Occidental’s $9.7 Billion Sale of OxyChem to Berkshire Hathaway
On October 2, 2025, Occidental, an international energy company, and Berkshire Hathaway announced a definitive agreement for Berkshire Hathaway to acquire Occidental’s chemical business, OxyChem, in an all‑cash transaction for $9.7 billion, subject to customary purchase price adjustments. Cravath is representing Occidental in connection with the transaction.
Deals & Cases
August 07, 2025
Paramount Global Completes Merger with Skydance
On August 7, 2025, Paramount Global and Skydance Media (“Skydance”) announced the completion of their merger, creating a standalone global media and entertainment company, Paramount, a Skydance Corporation (“Paramount”). Paramount Class B shares will begin trading today on the Nasdaq Stock Market LLC under “PSKY.” Cravath represented the Paramount Special Committee in connection with the transaction.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.